UnknownN/Aketamine

Auditory MMN EEG in TRD in Response to Ketamine

Sponsored by Unity Health Toronto

NCT ID
NCT05464264
Target Enrollment
30 participants
Start Date
2022-10-03
Est. Completion
2024-12

About This Study

To develop and test a neurocomputational model of ketamine treatment response predictions in TRD.

Conditions Studied

Treatment-resistant Depression (TRD)

Interventions

  • Ketamine

Eligibility

Age:18 Years - 65 Years
View full eligibility criteria
Inclusion Criteria:

1.18 to 65 years of age 2. Meeting Diagnostic and Statistical Manual for Mental Disorders (DSM-5) criteria for MDD and in a Major Depressive Episode and ≥10 on the Montgomery-Asberg Depression Rating Scale (MADRS).

3\. Competent to consent-based on their ability to provide a spontaneous narrative description of the key elements of the study.

4\. Failure of at least two trials of antidepressant therapy during the current episode (treatment-resistant depression) and receiving ketamine treatment clinically as administered by their clinician 5. Staying on stable dosages of any concomitant psychotropic medications.

Exclusion Criteria:

1. History of bipolar disorder or psychosis
2. Current substance use or history of substance use during the past year (excluding nicotine and caffeine use disorder)
3. Concomitant major and unstable medical or neurologic illness or a history of seizures.
4. Non-English-speaking individuals.

Study Locations (1)

St. Michael's Hospital
Toronto, Ontario, Canada

This trial is not recruiting

This study is currently not accepting new participants.

Find recruiting trials
Data Source
ClinicalTrials.gov

Last updated from source